New treatments for brain disease - towards market with a disruptive technology
| Reference number | |
| Coordinator | Key2Brain AB |
| Funding from Vinnova | SEK 3 000 000 |
| Project duration | November 2023 - March 2026 |
| Status | Completed |
| Venture | Acceleration of deep tech companies |
| Call | Acceleration of deep tech companies 2023 |
Important results from the project
The project has strengthened Key2Brain’s technology platform by establishing internal capacity for early-stage preclinical drug development. Headcount, revenue and operational capacity have increased, thus contributing to both technical and commercial maturity. Structured indication strategy work, focused communication development, and relationship-building with Sweden-based actors complementing internal expertise have generated valuable synergies with other internal projects.
Expected long term effects
The project is expected to deliver long-term impact through a strengthened expertise and scalable platform for the development of brain targeted therapies. Increased capacity and validated technology create conditions for continued innovation, expanded international collaborations, and the commercialization of new treatments in areas with significant unmet medical needs.
Approach and implementation
The project, an early-stage drug development initiative, focused on the design, production and characterization of novel molecules using an iterative workflow driven by experimental results. The main objective was to validate the technology through preclinical proof-of-concept studies. During the project, team, methods and internal laboratory capacity were established, increasing knowledge, a more efficient workflow and increased the ability to address emerging challenges.